The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 22, 2019

Filed:

Oct. 24, 2016
Applicant:

The Research Foundation for Mental Hygiene, Inc., Menands, NY (US);

Inventors:

James D. Clelland, New York, NY (US);

Catherine L. Clelland, New York, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/6883 (2018.01); G01N 33/50 (2006.01); C12Q 1/68 (2018.01); C12P 19/34 (2006.01); A61K 31/7052 (2006.01); A61K 33/00 (2006.01); A61K 45/06 (2006.01); A61K 31/519 (2006.01); A61K 33/14 (2006.01); A61K 31/5415 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6883 (2013.01); A61K 31/519 (2013.01); A61K 31/5415 (2013.01); A61K 31/7052 (2013.01); A61K 33/00 (2013.01); A61K 33/14 (2013.01); A61K 45/06 (2013.01); C12Q 1/68 (2013.01); G01N 33/50 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/302 (2013.01); G01N 2800/50 (2013.01);
Abstract

An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCH1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered BH4 system measures, is used to screen or diagnose subjects at risk for developing a psychiatric, neuropsychiatric, or neurological disorder. The genetic assay, with or without a biopterin or BH4 system assay, may also be used to determine treatment regimens. For subjects with an impaired BH4 system, treatments to increase or normalize biopterin, BH4, or the BH4 system can also be used, such as BH4 supplementation, lithium treatment, phenylalanine treatment, or other treatments and therapies.


Find Patent Forward Citations

Loading…